Citations

Showing 10 of 108162 citations.

Metric Development for the Multicenter Improving Pediatric Sepsis Outcomes (IPSO) Collaborative
Paul, Raina, Niedner, Matthew , Brilli, Richard J., Macias, Charles G. , Riggs, Ruth , Balamuth, Frances, Depinet, Holly, Larsen, Gitte , Huskins, Charlie, Scott, Halden F. , Lucasiewicz, Gloria, Schaffer, Melissa, Souza, Heidi G. De , Silver, Pete, Richardson, Troy , Hueschen, Leslie A. , Campbell, Deborah, Wathen, Beth, Auletta, Jeffery J. , INVESTIGATORS, FOR THE IPSO COLLABORATIVE, Frizzola, Meg , Auletta, Jeffery J , Balamuth, Fran , Schaffer, Melissa, Silver, Pete, INVESTIGATORS, FOR THE IPSO COLLABORATIVE, Schafer, Melissa

Mayo Clinic

Pediatrics | April 1, 2021 | Volume: 147 | Issue: 5 | Pages: No page available

10.1542/peds.2020-017889 | PMID 33795482 Get It

BACKGROUND: A 56 US hospital collaborative, Improving Pediatric Sepsis Outcomes, has developed variables, metrics and a data analysis plan to track quality improvement (QI)–based patient outcomes over time. Improving Pediatric Sepsis Outcomes expands on previous pediatric sepsis QI efforts by improving electronic data capture and uniformity across sites. METHODS: An expert panel developed metrics and corresponding variables to assess improvements across the care delivery spectrum, including the emergency department, acute care units, hematology and oncology, and the ICU. Outcome, process, and balancing measures were represented. Variables and statistical process control charts were mapped to each metric, elucidating progress over time and informing plan-do-study-act cycles. Electronic health record (EHR) abstraction feasibility was prioritized. Time 0 was defined as time of earliest sepsis recognition (determined electronically), or as a clinically derived time 0 (manually abstracted), identifying earliest physiologic onset of sepsis. RESULTS: Twenty-four evidence-based metrics reflected timely and appropriate interventions for a uniformly defined sepsis cohort. Metrics mapped to statistical process control charts with 44 final variables; 40 could be abstracted automatically from multiple EHRs. Variables, including high-risk conditions and bedside huddle time, were challenging to abstract (reported in <80% of encounters). Size or type of hospital, method of data abstraction, and previous QI collaboration participation did not influence hospitals’ abilities to contribute data. To date, 90% of data have been submitted, representing 200 007 sepsis episodes. CONCLUSIONS: A comprehensive data dictionary was developed for the largest pediatric sepsis QI collaborative, optimizing automation and ensuring sustainable reporting. These approaches can be used in other large-scale sepsis QI projects in which researchers seek to leverage EHR data abstraction.
Vasopressin-Dependent Disorders: What Is New in Children?
Driano, Jane E., Lteif, Aida, Creo, Ana L. , Lteif, Aida N

Mayo Clinic

Pediatrics | April 1, 2021 | Volume: 147 | Issue: 5 | Pages: No page available

10.1542/peds.2020-022848 | PMID 33795481 Get It

Arginine vasopressin (AVP)–mediated osmoregulatory disorders, such as diabetes insipidus (DI) and syndrome of inappropriate secretion of antidiuretic hormone (SIADH) are common in the differential diagnosis for children with hypo- and hypernatremia and require timely recognition and treatment. DI is caused by a failure to concentrate urine secondary to impaired production of or response to AVP, resulting in hypernatremia. Newer methods of diagnosing DI include measuring copeptin levels; copeptin is AVP’s chaperone protein and serves as a surrogate biomarker of AVP secretion. Intraoperative copeptin levels may also help predict the risk for developing DI after neurosurgical procedures. Copeptin levels hold diagnostic promise in other pediatric conditions, too. Recently, expanded genotype and phenotype correlations in inherited DI disorders have been described and may better predict the clinical course in affected children and infants. Similarly, newer formulations of synthetic AVP may improve pediatric DI treatment. In contrast to DI, SIADH, characterized by inappropriate AVP secretion, commonly leads to severe hyponatremia. Contemporary methods aid clinicians in distinguishing SIADH from other hyponatremic conditions, particularly cerebral salt wasting. Further research on the efficacy of therapies for pediatric SIADH is needed, although some adult treatments hold promise for pediatrics. Lastly, expansion of home point-of-care sodium testing may transform management of SIADH and DI in children. In this article, we review recent developments in the understanding of pathophysiology, diagnostic workup, and treatment of better outcomes and quality of life for children with these challenging disorders.
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Pacenta, Holly , Allen‐Rhoades, Wendy , Langenau, David M. , Houghton, Peter J. , Keller, Charles , Heske, Christine M. , Deel, Michael D. , Linardic, Corinne M. , Stewart, Elizabeth , Turpin, Brian , Harrison, Douglas J. , Khan, Javed , Mascarenhas, Leo , Skapek, Stephen X. , Meyer, William H. , Hawkins, Douglas S. , Hingorani, Pooja , Laetsch, Theodore W. , Mascarenhas, Leo , Skapek, Stephen X , Laetsch, Theodore W , Hawkins, Douglas S , Allen-Rhoades, Wendy A , Shern, Jack F. , Chen, Eleanor Y. , Amatruda, James F. , Linardic, Corinne M

Mayo Clinic

Journal of Clinical Medicine | April 1, 2021 | Volume: 10 | Issue: 7 | Pages: 1416

10.3390/jcm10071416 | PMID 33915882 Get It

Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children’s Oncology Group (COG) convened a rhabdomyosarcoma new agent task force in 2020 to systematically evaluate novel agents for inclusion in phase 2 or phase 3 clinical trials for patients diagnosed with rhabdomyosarcoma, following a similar effort for Ewing sarcoma. The task force was comprised of clinicians and basic scientists who collectively identified new agents for evaluation and prioritization in clinical trial testing. Here, we report the work of the task force including the framework upon which the decisions were rendered and review the top classes of agents that were discussed. Representative agents include poly-ADP-ribose polymerase (PARP) inhibitors in combination with cytotoxic agents, mitogen-activated protein kinase (MEK) inhibitors in combination with type 1 insulin-like growth factor receptor (IGFR1) inhibitors, histone deacetylase (HDAC) inhibitors, and novel cytotoxic agents.
Preparing Children for International Travel
Chehab, Hiba, Christenson, John C. , Fischer, Philip R.

Mayo Clinic

Pediatrics In Review | April 1, 2021 | Volume: 42 | Issue: 4 | Pages: 189-202

10.1542/pir.2018-0353 | PMID 33795465 Get It

Unmasking coupling between channel gating and ion permeation in the muscle nicotinic receptor
Strikwerda, John R. , Sine, Steven M.

Mayo Clinic

eLife | April 1, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.66225 | PMID 33821794 Get It

Whether ion channel gating is independent of ion permeation has been an enduring, unresolved question. Here, applying single channel recording to the archetypal muscle nicotinic receptor, we unmask coupling between channel gating and ion permeation by structural perturbation of a conserved intramembrane salt bridge. A charge-neutralizing mutation suppresses channel gating, reduces unitary current amplitude, and increases fluctuations of the open channel current. Power spectra of the current fluctuations exhibit low- and high-frequency Lorentzian components, which increase in charge-neutralized mutant receptors. After aligning channel openings and closings at the time of transition, the average unitary current exhibits asymmetric relaxations just after channel opening and before channel closing. A theory in which structural motions contribute jointly to channel gating and ion conduction describes both the power spectrum and the current relaxations. Coupling manifests as a transient increase in the open channel current upon channel opening and a decrease upon channel closing.
A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Managemen
Güleç, Seza , Ahuja, Sukhjeet, Avram, Anca M. , Bernet, Victor , Bourguet, P., Draganescu, Ciprian, Grant, Frederick D., Greenspan, Bennett S. , Hegedüs, László , Jonklaas, Jacqueline , Kloos, Richard T. , Luster, Markus , Tuttle, R. Michael , Bernet, Victor J, Giovanella, Luca , Jonklaas, Jacqueline , Kloos, Richard T , Elisei, Rossella , Giovanella, Luca , Oyen, Wim J.G. , Smit, Johannes W. A.

Mayo Clinic

Thyroid® | April 1, 2021 | Volume: 31 | Issue: 7 | Pages: 1009-1019

10.1089/thy.2020.0826 | PMID 33789450 Get It

Background: The American Thyroid Association (ATA), the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging have established an intersocietal working group to address the current controversies and evolving concepts in thyroid cancer management and therapy. The working group annually identifies topics that may significantly impact clinical practice and publishes expert opinion articles reflecting intersocietal collaboration, consensus, and suggestions for further research to address these important management issues. Summary: In 2019, the intersocietal working group identified the following topics for review and interdisciplinary discussion: (i) perioperative risk stratification, (ii) the role of diagnostic radioactive iodine (RAI) imaging in initial staging, and (iii) indicators of response to RAI therapy. Conclusions: The intersocietal working group agreed that (i) initial patient management decisions should be guided by perioperative risk stratification that should include the eighth edition American Joint Committee on Cancer staging system to predict disease specific mortality, the modified 2009 ATA risk stratification system to estimate structural disease recurrence, with judicious incorporation of molecular theranostics to further refine management recommendations; (ii) diagnostic RAI scanning in ATA intermediate risk patients should be utilized selectively rather than being considered mandatory or not necessary for all patients in this category; and (iii) a consistent semiquantitative reporting system should be used for response evaluations after RAI therapy until a reproducible and clinically practical quantitative system is validated.
Physical Activity May Reduce Apolipoprotein E4-Associated Cognitive Decline in Parkinson Disease
Darweesh, Sirwan K.L. , Savica, Rodolfo , Raber, Jacob , Savica, Rodolfo

Mayo Clinic

Neurology | April 1, 2021 | Volume: 96 | Issue: 19 | Pages: 877-878

10.1212/wnl.0000000000011851 | PMID 33790042 Get It

Pain Associated With Continuous Intravenous Infusion of Bumetanide: A Case Series
Herges, Lori B., Brighton, Diane D., Herges, Joseph R. , Ou, Narith N., Jentzer, Jacob C.

Mayo Clinic

Critical Care Nurse | April 1, 2021 | Volume: 41 | Issue: 2 | Pages: 44-50

10.4037/ccn2021833 | PMID 33791769 Get It

Introduction Bumetanide can induce generalized musculoskeletal pain when administered as a continuous infusion, an effect that may be underrecognized. The purpose of this case series is to educate health care providers about the incidence and presentation of pain associated with bumetanide infusions, adding to the existing literature describing this adverse event. Clinical Findings Of 40 critically ill patients, 15 (38%) had increased pain scores after initiation of a continuous infusion of bumetanide, with symptoms commonly occurring 12 to 24 hours after initiation of the infusion. Reported descriptions of the pain included generalized aching, soreness, burning, allodynia, headaches, and exacerbation of underlying pain in localized areas. Increases in patient-reported pain correlated directly with initiation of the continuous infusion of bumetanide. Diagnosis Four of the 15 bumetanide-associated pain events (27%) were recognized as such by the health care team. Interventions Bumetanide was promptly discontinued in the 4 identified cases. The 11 patients (73%) whose pain was not recognized as related to bumetanide remained on a continuous infusion of bumetanide and received pain medications including opioids. Infusions were stopped when patients transitioned to dialysis (n = 8 [53%]), began receiving comfort care (n = 5 [33%]), or completed diuresis therapy (n = 2 [13%]). Outcomes For all patients, pain symptoms resolved within 24 to 48 hours after discontinuation of bumetanide infusion with no significant electrolyte abnormalities. Conclusion Bumetanide-induced pain is more common than previously described. Early recognition of this adverse event can prevent patient discomfort and escalation of treatment.
Assessment of Children With Hearing Loss and Co-Occurring Medical Disorders: Challenging Cases
Brown, Taylor M. , Baas, Becky S. , Stoeckel, Ruth , Belf, L., Poling, Gayla L. , Brown, Taylor , Stoeckel, Ruth , Poling, Gayla L

Mayo Clinic

Perspectives of the ASHA Special Interest Groups | March 31, 2021 | Volume: 6 | Issue: 2 | Pages: 375-383

10.1044/2021_persp-20-00080 Get It

Purpose Assessing children with hearing loss and co-occurring medical disorders can be challenging. The purpose of this clinical focus article is to highlight multidisciplinary decision making and evaluation considerations when assessing communication skills of children with hearing loss and co-occurring disorders: velopharyngeal insufficiency, childhood apraxia of speech, and autism spectrum disorder. Method Case examples are described to illustrate multidisciplinary decision-making processes for assessing the communication skills of children with hearing loss who have co-occurring velopharyngeal insufficiency, childhood apraxia of speech, or autism spectrum disorder. Conclusions Clinicians must have knowledge of speech sound development, language development, and social communication for differential diagnosis and treatment planning for children with hearing loss and co-occurring disorders. A team-based approach is recommended when assessing and treating children with hearing loss. Speech-language pathologists and audiologists should feel comfortable recommending other professionals to help with differential diagnosis and treatment considerations when appropriate. Continued assessment and monitoring by a multidisciplinary team for individuals with hearing loss is recommended across the life-span.
Comparison of Survivors and Nonsurvivors of Diffuse Alveolar Hemorrhage: Risk Factors for In-hospital Death
Sangli, Swathi , Baqir, Misbah , Ryu, Jay H. , Ryu, Jay H

Mayo Clinic

No container title available | March 31, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-353894/v1 Get It

Abstract ObjectiveThe objective of this study was to identify the predictors of in-hospital mortality among patients with diffuse alveolar hemorrhage (DAH).Patients and MethodsWe conducted a retrospective review of 89 patients hospitalized for DAH at our institution between 2001 and 2017: 49 patients who died during hospitalization and 40 patients who survived were compared. We reviewed their presenting signs and symptoms, clinical course, radiologic and pathologic findings, along with medical management. We then performed univariate and multivariate analyses to identify the risk factors associated with in-hospital mortality.ResultsWe identified 12 factors to be associated with mortality when comparing survivor vs non-survivor cohorts: smoking (27 [67%] vs 21 [42%], p = 0.02), malignancy (7 [17%] vs 24 [49%], p = 0.002), interstitial lung disease (0 vs 7 [14%], p = 0.01), liver failure (1 [2%] vs 14 [28%], p = 0.001), autoimmune diseases (16 [40%] vs 4 [8%], p =0.0006), thrombocytopenia (3 [7%] vs 35 [71%], p <0.0001), ICU admission (23 [57%] vs 40 [85%], p=0.004), mean duration of ICU stay (3.5 days [± 6.7] vs 5.5 days [± 5.5], p = 0.4), steroid use (36 [90%] vs 31 [63%], p = 0.003), use of plasma exchange (6 [15%] vs 0, p = 0.005), use of mechanical ventilation (15 [37%] vs 36 [75%], p value = 0.0007) and development of acute respiratory distress syndrome (ARDS) (9 [22%] vs 37 [77%], p <0.0001), respectively. On multivariate analysis, thrombocytopenia (OR 52.08: 95% CI, 8.59-315.71; p <0.0001) and ARDS (OR 11.71: 95% CI, 2.60-52.67; p = 0.0013) were associated with higher odds of mortality in DAH while steroid use (OR 0.05: 95% CI, 0.007-0.39; p = 0.0004) was associated with a lower risk of in-hospital mortality in patients with DAH.ConclusionIn DAH, thrombocytopenia and ARDS were predictors of in-hospital mortality whereas the use of steroid was associated with a more favorable prognosis.